SPRY
ARS Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.62
−0.88%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 116.9M | 84.3M | 89.1M | 30.0K | 1.3M |
| Cost of Revenue | 30.5M | 20.4M | 20.6M | — | 17.1M |
| Gross Profit | 86.4M | 63.9M | 68.6M | 30.0K | (15.8M) |
| Operating Expenses | |||||
| R&D Expense | 15.2M | 13.2M | 19.6M | 20.3M | 18.4M |
| SG&A Expense | 284.5M | 230.1M | — | 47.3M | 18.7M |
| General & Admin Expense | 77.6M | — | — | 47.3M | 18.5M |
| Selling & Marketing Expense | — | — | — | — | 200.0K |
| Other Expenses | 3.0M | — | 52.1M | — | (17.3M) |
| Total Operating Expenses | 302.7M | 243.3M | 71.7M | 67.5M | 19.7M |
| Cost and Expenses | 333.2M | 263.7M | 92.2M | 67.5M | 36.8M |
| Operating Income (EBIT) | (216.3M) | (179.4M) | (3.1M) | (67.5M) | (35.5M) |
| Non-Operating | |||||
| Interest Income | 3.6M | 10.7M | — | — | — |
| Interest Expense | 4.9M | 2.6M | — | — | — |
| Net Interest Income | (1.3M) | 8.1M | — | — | — |
| Other Non-Op Income/Expense | 755.0K | 8.1M | 11.4M | 13.2M | 834.0K |
| Non-Operating Income (excl Interest) | (5.7M) | (10.7M) | (11.4M) | (13.2M) | (834.0K) |
| EBT (Pre-Tax Income) | (215.5M) | (171.4M) | 8.3M | (54.4M) | (34.7M) |
| Income Tax Expense | (80.0K) | (80.0K) | 288.0K | — | — |
| Bottom Line | |||||
| Net Income | (215.4M) | (171.3M) | 8.0M | (54.4M) | (34.7M) |
| Earnings from Cont. Ops | (215.4M) | (171.3M) | 8.0M | (54.4M) | (34.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (215.4M) | (171.3M) | 8.0M | (54.4M) | (34.7M) |
| Per Share | |||||
| Basic EPS | ($2.18) | ($1.74) | $0.08 | ($0.57) | ($0.87) |
| Diluted EPS | ($2.18) | ($1.74) | $0.08 | ($0.57) | ($0.87) |
| Revenue Per Share | $1.18 | $0.86 | $0.92 | $0.00 | $0.03 |
| Shares | |||||
| Basic Shares Outstanding | 99.3M | 98.6M | 96.9M | 95.2M | 40.0M |
| Diluted Shares Outstanding | 99.3M | 98.6M | 102.4M | 95.2M | 40.0M |
| Profitability Metrics | |||||
| EBITDA | (207.0M) | (167.4M) | 8.4M | (54.3M) | (34.4M) |
| D&A | 3.6M | 1.4M | 79.0K | 73.0K | 319.0K |
| EBIT | (210.6M) | (168.8M) | 8.3M | (54.4M) | (34.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026